OrthoPediatrics Corp. KIDS

Milestone program with record attendance brought together 39 participants from 23 institutions across 22 cities and three countriesWARSAW, Ind., Oct. 01, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it sponsored the 10th Pediatric Orthopedic Surgical Techniques (POST) Course, which brought together a record 39 participants from 23 institutions acro

WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the recent implantation of the 1,000th Tibia Nail using its latest Pediatric Nailing Platform (PNP). The PNP Tibia System was designed to bring a world-class, pediatric-focused nailing system to surgeons, enabling the use of rigid tibial nails in pediatric patients. OrthoPediatric

Activists report to the SEC on Privia Health Group, Group 1 Automotive, MarineMax, OrthoPediatrics, and Dell Technologies.

On August 4, OrthoPediatrics Corp. (NASDAQ:KIDS) reported second-quarter results that pushed revenue past $70 million for the first time in company history. The pediatric orthopedics specialist posted $70.5 million in total revenue, up 15% from $61.1 million a year earlier, and used the momentum to raise its full-year outlook. For a company that has spent […]

Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating TechnologyWARSAW, Ind., Aug. 25, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the full commercial launch of its 3P™ Pediatric Plating Platform® Hip System. Following a highly successful limited launch period that resulted in over 350 surgical implantations, the system is now

Moby summary of OrthoPediatrics Corp.'s Q2 2026 earnings call

OrthoPediatrics Corp (KIDS) posts 15% revenue growth and raises full-year guidance amid strong trauma and deformity performance.

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +16.13% and +3.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Second Quarter 2026 Revenue Surpasses $70 million for the First Time in Company History, and Increased 15% Year-over-YearWARSAW, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 and Business Highlights Helped a record of nearly 46,000 children in the se

WARSAW, Ind., July 29, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, held in Boston, MA. Event: Canaccord Genuity 46th Annu

WARSAW, Ind., July 21, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 4, 2026 at 4:30 p.m. ET to discuss the results. Investors interested in listening to

OrthoPediatrics is back in focus after recent Street research prompted both upward and downward revisions to the stock’s price target, including a US$1 lift in the consensus level alongside US$3 cuts from more cautious analysts. The mixed reaction captures how different firms are interpreting the same set of assumptions and news flow, with some emphasizing long term growth potential and others stressing execution and margin risk. As you read on, you will see how these shifting price targets...

WARSAW, Ind., June 24, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced an exclusive distribution agreement with OSSIO, Inc. (“OSSIO”) that brings U.S. children’s hospitals nationwide a bio-integrative, metal-free fixation technology ideally suited for treatment of fractures and deformities in pediatric patients. After performing their fixation functio

OrthoPediatrics enters this update cycle with no change to its existing price target, giving you a steady reference point as the story develops. Even without a fresh valuation reset or new analyst commentary to dissect, the lack of movement can still tell you something about how expectations are holding. Read on to see how to track this kind of quiet update and follow the evolving narrative around the stock. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other...

WARSAW, Ind., May 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Fred Hite, Chief Operating Officer, and Chief Financial Officer, is scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference, held in Miami Beach, FL. Event: Goldman Sachs 47th Annual Global Healthcare Conference 2026Format: Fire

The blended fair value estimate for OrthoPediatrics has shifted from US$24.00 to about US$24.67 per share, reflecting a modest adjustment to the stock’s perceived potential. This move sits alongside a split in Street views, where some analysts have raised targets into the low US$20s while others have trimmed their numbers, leaving the overall narrative more finely balanced. As you read on, you will see how this evolving analyst debate can help you frame your own view on the stock. Analyst...